Table 4
From the following article
India's health biotech sector at a crossroads
Sarah E Frew, Rahim Rezaie, Stephen M Sammut, Monali Ray, Abdallah S Daar & Peter A Singer
Nature Biotechnology 25, 403 - 417 (2007)
doi:10.1038/nbt0407-403
Table 4. Alliances/collaborations between companies interviewed and domestic organizations
| Company name | Indian alliances and objective |
|---|---|
CSIR, India's Council of Scientific and Industrial Research. | |
| Avestha Gengraine Technologies | Collaboration with Cipla (Mumbai) to develop a number of biosimilar molecules to be marketed by Cipla. Working with state governments and public institutions such as CSIR for a variety of purposes and has a relationship with St. John's Medical Academy for conducting clinical trials. Collaborative research agreement with Ranbaxy (Gurgaon) for new drug development relating to construction of recombinant cell lines required for screening Ranbaxy's drug candidates. PhD training program with Mysore University |
| Bharat Biotech International | Received certain technologies from various domestic institutes such as the Indian Institute of Chemical Technology (IICT, Hyderabad). Developed lysostaphin with the Institute of Genomics & Integrative Biology (IGIB, New Delhi), a CSIR lab, through the New Millennium Indian Technology Leadership Initiative program. Work with All India Institute of Medical Sciences (AIIMS), New Delhi and Indian Institute of Science (IISc), Bangalore for development of rotavirus vaccine. Comarketing with Wockhardt, Intas, Nicholas Piramal, VHB and Lupin for various different products. Partnered with International Center for Genetic Engineering and Biotechnology (ICGEB) to develop a malaria vaccine |
| Bhat Bio-Tech India | Joint projects and PhD-training program with IISc and other institutions in Bangalore |
| Biocon | Provided some funding for XCyton Diagnostics (Bangalore), a diagnostics company |
| Biological E | Some work with IISc. Outsource IP work and data management for clinical trials to Indian agencies |
| Dr. Reddy's Laboratories | Sponsoring projects at various domestic institutions such as the IISc and IICT. Bhabha Atomic Research Centre (BARC, Mumbai) for access to radiation |
| Indian Immunologicals | Five-year collaboration with IISc for basic research, animal testing and DNA rabies vaccine. Collaborated with IISc (Bangalore) to develop world's first combination human rabies vaccine containing DNA vaccine and a low dose of cell culture vaccine. Outsources clinical trials to Indian contract research organizations |
| LifeCare Innovations | Post Graduate Institute of Medical Education & Research: Chandigarh Bio-chemistry Department. Collaborative development of anti-TB and other anti-infective controlled release pharmaceuticals and evaluation of antifungals at Mycology Division. Panjab University. Collaborative development of liposomal pharmaceuticals. SGS Medical College & KEM Hospital (Mumbai). Clinical studies and trials. AIIMS (New Delhi). Preclinical studies of antileishmanial drug delivery system. Indian Institute of Technology (Kanpur). Materials development. CellMax. Collaborative development and marketing of recombinant biotherapeutics and medical diagnostics |
| Nicholas Piramal India | Several collaborations with CSIR labs, NII, IGIB and National Institute of Oceanography, Regional Research Laboratory in Jammu. Collaboration with IISc for anti-infectives. Work with Anna University (Chennai) on use of traditional medicine for oncology and inflammation. Collaboration with CDRI for work on malaria and diabetes |
| Panacea Biotec | Technology transfer and vaccine development for recombinant anthrax vaccine, developed at Jawaharlal Nehru University through Biotech Consortium India. Technology transfer and vaccine development for Japanese encephalitis vaccine; developed at National Institute of Immunology. Technology transfer and development of foot-and-mouth disease vaccine developed by Indian Veterinary Research Institute, through National Research Development Corporation. Clinical trials done in a network of medical institutes through Indian contract research organizations |
| Reliance Life Sciences | Technology development partnerships with national institutes |
| Shantha Biotechnics | Working together with the Centre for Cellular & Molecular Biology (CCMB) for development of novel expression vectors. Financial support for scientists at the International Centre for Genetic Engineering and Biotechnology (ICGEB, New Delhi) for development of kinase inhibitors as cancer treatment. Collaboration with NII to develop vaccines based on nanotechnology. Some work conducted at BARC for developing plant-based products such as proteins and vaccines |
| Strand Life Sciences | St. John's Hospital (Bangalore) and Central Drug Research Institute (Lucknow) on hepatoxicity. Created a diabetic registry with Clinigene to gather serological data to profile patients at risk of developing nephropathy. Syngene is a synthesis partner for target focused molecular libraries. Work with CSIR labs on three-dimensional-visualization platform for bioprocesses |
| Syngene | IISc collaboration on expression in Pichia pastoris. Indian Association of Cultivation of Science (IACS, Calcutta) in synthetic chemistry. Links formed with public institutions to give scientists an outlet to be creative and explore subject areas of interest, provided these activities do not conflict with contract work conducted for their clients |
| Transgene Biotek | Collaborations with CSIR institute for the development of oral delivery platform technologies. Collaborative partnership with an Indian university to develop transgenic rabies vaccine |
| Wockhardt | Joint research programs with universities and research institutes as well as production and operational relationships with other firms |
